Fusion Pharmaceuticals Q1 2024 GAAP EPS $(0.40) Misses $(0.37) Estimate
Portfolio Pulse from Benzinga Newsdesk
Fusion Pharmaceuticals reported a Q1 2024 GAAP EPS loss of $(0.40), missing the consensus estimate of $(0.37) by 8.11%. This represents an 11.11% improvement over the previous year's loss of $(0.45) per share.
May 07, 2024 | 11:08 am
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Fusion Pharmaceuticals reported a Q1 2024 GAAP EPS loss of $(0.40), missing the consensus estimate of $(0.37) by 8.11%, but improved from last year's $(0.45) loss.
Missing the consensus estimate typically has a negative short-term impact on a stock's price, as it may lead to reduced investor confidence. However, the improvement over last year's loss indicates progress, which might mitigate some negative perceptions.
CONFIDENCE 90
IMPORTANCE 75
RELEVANCE 100